Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target refers to the molecular complex and signaling pathways through which Angiostatin and related anti-angiogenic agents exert their effects on endothelial cells. It is characterized by its ability to inhibit endothelial cell proliferation and migration while simultaneously downregulating the expression of urokinase-type plasminogen activator (uPA). Key identified components of this target system include surface-expressed ATP synthase, which Angiostatin inhibits to trigger endothelial apoptosis, and Angiomotin, which regulates cell motility. In disease states, particularly cancer, this target is exploited to suppress tumor-induced neovascularization and metastasis by preventing the degradation of the extracellular matrix. Therapeutic intervention at this target aims to starve tumors of their blood supply and limit their invasive potential.
Inhibition of endothelial cell surface ATP synthase to deplete intracellular ATP; binding to Angiomotin to disrupt cell migration; downregulation of uPA expression to prevent matrix degradation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiostatin receptor (multiple binding partners including ATP synthase and Angiomotin) (Angiostatin Target).